A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
Study Identifier:
ALXN1210-HV-104
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1210
Date
Apr 2016 - Jul 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years
Requirements Information
Sex
Female & Male
Age
25 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1210
Date
Apr 2016 - Jul 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years years
Requirements Information
Protocol Summary
This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams \[mg\]) of ALXN1210 following intravenous administration to healthy Japanese participants.
Trial Locations
Location
Status
Location
Clinical Trial Site
London, United Kingdom
Status
N/A